Upendra P. Hegde

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

Sarah B. Goldberg, Scott Gettinger, Amit Mahajan et al. · The Lancet Oncology · 2016 · 996 citations · Full text

Medicine, Oncology, Pharmacology +16

High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology

Upendra P. Hegde, Armando Filie, Richard F. Little et al. · Blood · 2004 · 353 citations · Full text

Medicine, Hematology, Oncology +12

Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers

Wyndham H. Wilson, Kieron Dunleavy, Stefania Pittaluga et al. · Journal of Clinical Oncology · 2008 · 307 citations · Full text

Medicine, Hematology, Oncology +17

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial

Harriet M. Kluger, Veronica Chiang, Amit Mahajan et al. · Journal of Clinical Oncology · 2018 · 277 citations

Medicine, Oncology, Immunotherapy +16